The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Shasqi, Johnson & Johnson expand existing research collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Shasqi, Inc. and Johnson & Johnson Enterprise Innovation Inc. have expanded their ongoing research collaboration.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In the Archives

53 Nobel Prizes and counting: ACS celebrates a legacy of funding research

In a new article on the Cancer History Project, the American Cancer Society profiles three ACS-funded Nobel laureates:  David Baker, PhD2024 Nobel PrizeChemistry Victor Ambrose, PhD 2024 Nobel Prize Physiology or Medicine Gary Ruvkun, PhD2024 Nobel Prize Physiology or Medicine They join a cohort of 50 other ACS-funded Nobel laureates.  “The American Cancer Society’s legacy, with 53 Nobel...

In Brief

Victor Ambros and Gary Ruvkun share 2024 Nobel Prize in Physiology or Medicine

Victor AmbrosPhoto credit: Niklas Elmehed © Nobel Prize OutreachGary RuvkunPhoto credit: Niklas Elmehed © Nobel Prize OutreachVictor Ambros and Gary Ruvkun were jointly awarded the 2024 Nobel Prize in Physiology or Medicine from the Nobel Assembly at the Karolinska Institutet. The two scientists are being honored for their discovery of microRNA and its role in post-transcriptional gene regulation.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account